Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report
Abstract Background Idarucizumab is a specific antidote for the anticoagulant dabigatran. Although its efficacy has been recently reported, the drug is still in postmarketing surveillance and requires case data in different emergency settings. A newer intravenous thrombolytic therapy with recombinan...
Main Authors: | Toshiyuki Ohtani, Ryosuke Sintoku, Tasuku Yajima, Naoyuki Kaneko |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13256-019-2326-y |
Similar Items
-
Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report
by: Dan Xie, et al.
Published: (2021-12-01) -
Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy
by: Ilga Kikule, et al.
Published: (2022-09-01) -
Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
by: Gorana Vukorepa, et al.
Published: (2020-01-01) -
Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report
by: Waldemar Kafke, et al.
Published: (2016-06-01) -
Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature
by: Senta Frol, et al.
Published: (2021-06-01)